Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

Salim S. Virani,Julia M. Akeroyd,Sidney C. Smith,Mouaz H. Al-Mallah,Thomas M. Maddox,Pamela B. Morris,Laura A. Petersen,Christie M. Ballantyne,Scott M. Grundy,Neil J. Stone

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

2019

Salim S. Virani
Julia M. Akeroyd
Sidney C. Smith
Mouaz H. Al-Mallah
Thomas M. Maddox
Pamela B. Morris
Laura A. Petersen
Christie M. Ballantyne
Scott M. Grundy
Neil J. Stone

The 2018 American Heart Association/American College of Cardiology Multisociety Cholesterol Guidelines [(1)][1] recommend risk stratification among patients with atherosclerotic cardiovascular disease (ASCVD) to identify “very high-risk ASCVD patients.” These patients have characteristics

Keywords:

Internal medicine
Cardiology
Atherosclerotic cardiovascular disease
Diabetes mellitus
Cholesterol
Medicine
risk stratification
very high risk

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations